Technology
Why FastPharming?
FastPharming overcomes issues presented by mammalian expression systems:
CDMO Services
iBio offers a full range of development and manufacturing services to move your projects from pre-clinical to market launch. Our FastPharming® System shortens your development timelines and provides for seamless scale-up. Our Glycaneering™ Technology affords greater control and can deliver increased product potency and quality. We offer a range of recombinant products including monoclonal antibodies, antigens for subunit vaccine design, lysosomal enzymes, and many more.
Faster
Greater speed-to-clinic by shaving months off traditional mammalian-cell development times
Easier
Vertical farming eliminates scaling issues moving to large bioreactors – just use more hydroponically-grown plants
Better
Excellent glycosylation controls for better performance without freedom-to-operate issues
Eco-Friendly
Reduced volume of single-use disposables widely used in mammalian cell culture production
Robust
Reduced contamination risk since mammalian viruses and prions can’t grow in plants
Versatile
The system can express a wide range of recombinant proteins, including monoclonal antibodies, growth factors & cytokines, lysosomal enzymes, peptides, virus-like particles, and more
Speed to Clinic
- Rapid Agrobacterium vector availability accelerates the timeline to Master Cell Bank (MCB) generation by as much as 10 months
- Bulk drug substance manufacturing timeline reduced because host plants can be ready on-demand thereby eliminating the seed train
- Rapid production timeline can support earlier preclinical safety and product stability studies which can potentially further reduce time to IND
Mammalian cell culture timelines given above are for illustrative purposes only based upon competitive data from publicly available sources. Actual timelines may vary.
